Literature DB >> 23768778

Late effects of adjuvant chemotherapy for adult onset non-CNS cancer; cognitive impairment, brain structure and risk of dementia.

Vincent Koppelmans1, Monique M B Breteler, Willem Boogerd, Caroline Seynaeve, Sanne B Schagen.   

Abstract

Few studies have investigated the late (i.e. ≥ 5 years post-treatment) effects of chemotherapy for non-central nervous system (non-CNS) cancer on the brain. Here we discuss the studies that have investigated the late effects of adjuvant chemotherapy for non-CNS cancer on cognitive function (n=6); brain structure and function (n=5); and incidence of dementia (n=4). The neuropsychological studies showed long-term adverse cognitive problems in chemotherapy-exposed breast cancer survivors. This is in line with results from neuroimaging studies that report long-term brain structural alterations after chemotherapy. The studies exploring the association between chemotherapy and the incidence of dementia were contradictive and showed no clear relationship between the two phenomena. Although several methodological issues limit the validity and interpretation of some of the results of these studies, they suggest that chemotherapy is associated with subtle, yet long-lasting cognitive deficits, possibly related to brain structural and functional differences, but as yet not with an increased risk of dementia.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Chemotherapy; Cognition; Dementia; Long-term effects; Neuroimaging

Mesh:

Substances:

Year:  2013        PMID: 23768778     DOI: 10.1016/j.critrevonc.2013.04.002

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  30 in total

1.  AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015.

Authors:  Cornelia Liedtke; Marc Thill; Volker Hanf; Florian Schuütz
Journal:  Breast Care (Basel)       Date:  2015-06-18       Impact factor: 2.860

Review 2.  What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research.

Authors:  Annalynn M Williams; Clive S Zent; Michelle C Janelsins
Journal:  Br J Haematol       Date:  2016-07-08       Impact factor: 6.998

3.  The usefulness of sLORETA in evaluating the effect of high-dose ARA-C on brain connectivity in patients with acute myeloid leukemia: an exploratory study.

Authors:  A Zarabla; S Ungania; A Cacciatore; A Maialetti; G Petreri; A Mengarelli; A Spadea; F Marchesi; D Renzi; Svitlana Gumenyuk; L Strigari; Marta Maschio
Journal:  Funct Neurol       Date:  2017 Oct/Dec

4.  Brain network alterations and vulnerability to simulated neurodegeneration in breast cancer.

Authors:  Shelli R Kesler; Christa L Watson; Douglas W Blayney
Journal:  Neurobiol Aging       Date:  2015-05-01       Impact factor: 4.673

5.  Perceived cognitive function for breast cancer survivors: association of genetic and behaviorally related variables for inflammation.

Authors:  Jamie S Myers; Theresa A Koleck; Susan M Sereika; Yvette P Conley; Catherine M Bender
Journal:  Support Care Cancer       Date:  2017-03-01       Impact factor: 3.603

6.  AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2014.

Authors:  Volker Hanf; Florian Schütz; Cornelia Liedtke; Marc Thill
Journal:  Breast Care (Basel)       Date:  2014-07       Impact factor: 2.860

Review 7.  Default mode network as a potential biomarker of chemotherapy-related brain injury.

Authors:  Shelli R Kesler
Journal:  Neurobiol Aging       Date:  2014-05-15       Impact factor: 4.673

8.  Pupillary response: cognitive effort for breast cancer survivors.

Authors:  Jamie S Myers; Melike Kahya; Melissa Mitchell; Junqiang Dai; Jianghua He; Sanghee Moon; Kevin Hamilton; Mary Valla; Anne O'Dea; Jennifer Klemp; Monica Kurylo; Abiodun Akinwuntan; Hannes Devos
Journal:  Support Care Cancer       Date:  2018-08-10       Impact factor: 3.603

Review 9.  Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults.

Authors:  Jeffrey S Wefel; Shelli R Kesler; Kyle R Noll; Sanne B Schagen
Journal:  CA Cancer J Clin       Date:  2014-12-05       Impact factor: 508.702

10.  Frontal hypometabolism in elderly breast cancer survivors determined by [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET): a pilot study.

Authors:  Laura L Boles Ponto; Yusuf Menda; Vincent A Magnotta; Torricia H Yamada; Natalie L Denburg; Susan K Schultz
Journal:  Int J Geriatr Psychiatry       Date:  2014-09-01       Impact factor: 3.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.